Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $815871.0.

  • China Pharma Holdings' Cost of Revenue fell 4963.14% to $815871.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 3964.72%. This contributed to the annual value of $6.5 million for FY2024, which is 1066.6% down from last year.
  • Latest data reveals that China Pharma Holdings reported Cost of Revenue of $815871.0 as of Q3 2025, which was down 4963.14% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Cost of Revenue peaked at $2.9 million during Q4 2022, and registered a low of $815871.0 during Q3 2025.
  • Its 5-year average for Cost of Revenue is $1.8 million, with a median of $1.8 million in 2022.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 5590.95% in 2024, then plummeted by 4963.14% in 2025.
  • Quarter analysis of 5 years shows China Pharma Holdings' Cost of Revenue stood at $2.6 million in 2021, then increased by 11.24% to $2.9 million in 2022, then fell by 22.56% to $2.2 million in 2023, then tumbled by 41.92% to $1.3 million in 2024, then plummeted by 36.98% to $815871.0 in 2025.
  • Its last three reported values are $815871.0 in Q3 2025, $1.1 million for Q2 2025, and $1.3 million during Q1 2025.